Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01201850 · ClinicalTrials.gov registry record · NA
The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT01201850 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 7 participants.
The verdict
NCT01201850, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is being done to learn about the safety of the study drug bevacizumab(Avastin®), when used to treat radiation necrosis. The primary objective of this study is to test the feasibility of treating Central Nervous System (CNS) tumor patients suffering from radiation necrosis with bevacizumab every 2 weeks. The secondary objectives of this study are: * To evaluate improvement in neurologic symptoms associated with bevacizumab as assessed by clinical evaluation; * To investigate the neuro-imaging changes in radiation necrosis associated edema, including Mass Resonance (MR) spectroscopy; * To evaluate changes in corticosteroid use in patients with radiation necrosis following treatment with bevacizumab; * To evaluate changes in quality of life.
Interventions
- DRUG Bevacizumab (Avastin®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-06-28 |
| Est. Completion | 2016-08-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01201850
The ClinicalTrials.gov registry entry for NCT01201850 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab (Avastin®) is the first listed.
NCT01201850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01201850 about?
NCT01201850 is a clinical study titled "The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors". This study is being done to learn about the safety of the study drug bevacizumab(Avastin®), when used to treat radiation necrosis. The primary objective of this study is to test the feasibility of treating Central Nervous System (CNS) tumor patients suffering from radiation necrosis with bevacizuma...
What is the current status of trial NCT01201850?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2010-06-28. Estimated completion is 2016-08-04.
What interventions are being tested in trial NCT01201850?
The interventions under investigation include: Bevacizumab (Avastin®) (DRUG).
Who is sponsoring clinical trial NCT01201850?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.